

Kimmmie Ng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7482940/publications.pdf>

Version: 2024-02-01

71
papers

6,348
citations

117625

34
h-index

91884

69
g-index

71
all docs

71
docs citations

71
times ranked

10781
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer. <i>Science</i> , 2017, 358, 1443-1448.	12.6	983
2	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. <i>Cell Reports</i> , 2016, 15, 857-865.	6.4	671
3	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1086-1095.	1.6	383
4	Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women. <i>JAMA Oncology</i> , 2019, 5, 37.	7.1	305
5	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2014, 19, 637-638.	3.7	292
6	Circulating 25-Hydroxyvitamin D Levels and Survival in Patients With Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2984-2991.	1.6	277
7	Rising incidence of early-onset colorectal cancer – a call to action. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 230-243.	27.6	276
8	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , 2018, 8, 1096-1111.	9.4	256
9	Spatially organized multicellular immune hubs in human colorectal cancer. <i>Cell</i> , 2021, 184, 4734-4752.e20.	28.9	256
10	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. <i>Cell</i> , 2021, 184, 6119-6137.e26.	28.9	201
11	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. <i>JAMA Oncology</i> , 2018, 4, 783.	7.1	147
12	Effect of High-Dose vs Standard-Dose Vitamin D ³ Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1370.	7.4	134
13	Development and Validation of the PREMM ₅ Model for Comprehensive Risk Assessment of Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2017, 35, 2165-2172.	1.6	126
14	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. <i>Cell</i> , 2021, 184, 6262-6280.e26.	28.9	125
15	Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 345.	6.3	115
16	Sedentary Behaviors, TV Viewing Time, and Risk of Young-Onset Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky073.	2.9	110
17	Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer. <i>Gastroenterology</i> , 2018, 154, 906-915.e7.	1.3	93
18	Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. <i>Journal of Cancer</i> , 2015, 6, 1099-1104.	2.5	89

#	ARTICLE	IF	CITATIONS
19	Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , 2011, 29, 1599-1606.	1.6	85
20	Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. <i>Cancer Cell</i> , 2017, 31, 576-590.e8.	16.8	84
21	Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus. <i>Journal of Clinical Oncology</i> , 2015, 33, 29-35.	1.6	83
22	Cigarette Smoking and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2017, 35, 1822-1828.	1.6	78
23	Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. <i>Gastroenterology</i> , 2021, 160, 1373-1383.e6.	1.3	77
24	Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1540-1551.	6.3	69
25	Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial. <i>American Journal of Clinical Nutrition</i> , 2014, 99, 587-598.	4.7	62
26	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1003-1012.	6.3	59
27	Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens. <i>Clinical Cancer Research</i> , 2013, 19, 3987-3995.	7.0	57
28	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2018, 36, 1112-1120.	1.6	50
29	Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016, 34, 2899-2905.	1.6	49
30	Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. <i>JAMA Network Open</i> , 2021, 4, e2112539.	5.9	48
31	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. <i>Cancer Research</i> , 2016, 76, 7160-7167.	0.9	46
32	Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. <i>Gastroenterology</i> , 2015, 149, 614-622.	1.3	44
33	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019, 25, 7497-7505.	7.0	44
34	Leucocyte telomere length, genetic variants at the <i>TERT</i> gene region and risk of pancreatic cancer. <i>Gut</i> , 2017, 66, 1116-1122.	12.1	39
35	Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. <i>Cancer Discovery</i> , 2020, 10, 1690-1705.	9.4	38
36	Targeting the epidermal growth factor receptor in metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 8-20.	4.4	37

#	ARTICLE	IF	CITATIONS
37	Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 995-1002.	6.4	31
38	Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. <i>Carcinogenesis</i> , 2015, 36, 999-1007.	2.8	28
39	Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2019, 37, 159-165.	2.6	28
40	Vitamin D and Physical Activity in Patients With Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 223-231.	2.0	26
41	Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 2062-2069.	2.5	26
42	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	6.3	24
43	Predicted 25(OH)D Score and Colorectal Cancer Risk According to Vitamin D Receptor Expression. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1628-1637.	2.5	23
44	Null Association between Vitamin D and PSA Levels among Black Men in a Vitamin D Supplementation Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1944-1947.	2.5	22
45	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	2.9	22
46	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751.	1.6	20
47	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). <i>Journal of the National Cancer Institute</i> , 2019, 111, 170-179.	6.3	19
48	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 999-1008.	2.5	19
49	US Preventive Services Task Force Recommendations for Colorectal Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1943.	7.4	19
50	Sugar-sweetened beverage and sugar consumption and colorectal cancer incidence and mortality according to anatomic subsite. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1481-1489.	4.7	16
51	Individual participant data (IPD)-level meta-analysis of randomised controlled trials to estimate the vitamin D dietary requirements in dark-skinned individuals resident at high latitude. <i>European Journal of Nutrition</i> , 2022, 61, 1015-1034.	3.9	15
52	A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. <i>Investigational New Drugs</i> , 2020, 38, 1533-1539.	2.6	13
53	Joint Effects of Colorectal Cancer Susceptibility Loci, Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e92212.	2.5	12
54	Risk of Hypercalcemia in Blacks Taking Hydrochlorothiazide and Vitamin D. <i>American Journal of Medicine</i> , 2014, 127, 772-778.	1.5	10

#	ARTICLE	IF	CITATIONS
55	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2018, 2, pky017.	2.9	10
56	Vitamin D supplementation: a potential therapeutic agent for metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2020, 123, 1205-1206.	6.4	9
57	Obesity and efficacy of vitamin D3 supplementation in healthy black adults. <i>Cancer Causes and Control</i> , 2020, 31, 303-307.	1.8	9
58	Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival. <i>British Journal of Cancer</i> , 2021, 125, 1016-1024.	6.4	9
59	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. <i>Cancer Research</i> , 2021, 81, 3134-3143.	0.9	8
60	Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months. <i>Scientific Reports</i> , 2015, 5, 10411.	3.3	7
61	Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. <i>Cancers</i> , 2020, 12, 3451.	3.7	6
62	Genome-Wide Gene-€Diabetes and Gene-€Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1784-1791.	2.5	5
63	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. <i>Cancer Research</i> , 2020, 80, 4004-4013.	0.9	5
64	Pioneering a new care model for young-onset colorectal cancer: innovations in clinical care and scientific discovery. <i>Colorectal Cancer</i> , 2020, 9, CRC18.	0.8	5
65	Reduction of parathyroid hormone with vitamin D supplementation in blacks: a randomized controlled trial. <i>BMC Nutrition</i> , 2015, 1, .	1.6	3
66	To Treat or Not to Treat: Adjuvant Therapy for Stage II Colon Cancer in the Era of Precision Oncology. <i>Journal of Oncology Practice</i> , 2017, 13, 242-244.	2.5	3
67	Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. <i>Journal of Geriatric Oncology</i> , 2022, 13, 469-479.	1.0	3
68	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. <i>Oncologist</i> , 2022, 27, 292-298.	3.7	2
69	Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. <i>BMJ Open Sport and Exercise Medicine</i> , 2022, 8, e001353.	2.9	2
70	Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-102.	1.6	1
71	Response. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv150-djv150.	6.3	0